Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionShell Asset Management Co
Latest Disclosed Ownership2,142 shares
Latest Disclosed Value $ 51
Shell Asset Management Co reports 60.32% decrease in ownership of TVTX / Travere Therapeutics, Inc.

On November 7, 2025 - Shell Asset Management Co filed a 13F-HR form disclosing ownership of 2,142 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $51,194 USD as of September 30, 2025. The entity filed a previous 13F-HR on July 23, 2025 disclosing 5,398 shares of Travere Therapeutics, Inc.. The current value of the position is $98,082 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-11-07 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 2,142 -3,256 -60.32 0 0.0051
2025-07-23 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 5,398 -580 -9.70 0 0.0028
2025-05-14 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 5,978 -69 -1.14 0 0.0051
2025-02-14 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 6,047 -301 -4.74 0 0.0046
2024-11-07 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 6,348 -356 -5.31 0 0.0039
2024-07-25 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 6,704 -452 -6.32 0 0.0025
2024-02-14 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 7,156 -2,151 -23.11 0 0.0030
2023-11-08 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 9,307 -147 -1.55 0 0.0034
2023-07-28 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 9,454 -54 -0.57 0 0.0057
2023-05-15 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 9,508 -33 -0.35 0 0.0089
2023-02-07 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 9,541 -1,936 -16.87 0 -100.00 0.0088
2022-11-14 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 11,477 -3,008 -20.77 283 -19.37 0.0110
2022-08-09 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 14,485 24 0.17 351 -5.90 0.0104
2022-05-04 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 14,461 -2,140 -12.89 373 -27.57 0.0088
2022-02-09 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 16,601 74 0.45 515 28.43 0.0106
2021-11-04 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 16,527 -710 -4.12 401 59.76 0.0090
2021-08-12 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 17,237 930 5.70 251 -38.33 0.0049
2021-05-10 2021-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 16,307 9,426 136.99 407 116.49 0.0081
2021-02-16 2020-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 6,881 0 0.00 188 48.03 0.0039
2020-11-13 2020-09-30 13F RETROPHIN COM 761299106 6,881 0 0.00 127 -9.29 0.0030
2020-08-10 2020-06-30 13F RETROPHIN COM 761299106 6,881 -71 -1.02 140 38.61 0.0035
2020-05-11 2020-03-31 13F RETROPHIN COM 761299106 6,952 -105 -1.49 101 1.00 0.0028
2020-02-13 2019-12-31 13F RETROPHIN COM 761299106 7,057 -149 -2.07 100 19.05 0.0022
2019-11-12 2019-09-30 13F RETROPHIN COM 761299106 7,206 -62 -0.85 84 -42.47 0.0019
2019-08-12 2019-06-30 13F RETROPHIN COM 761299106 7,268 -165 -2.22 146 -13.10 0.0032
2019-05-09 2019-03-31 13F RETROPHIN COM 761299106 7,433 0 0.00 168 0.00 0.0037
2019-02-13 2018-12-31 13F RETROPHIN COM 761299106 7,433 -600 -7.47 168 -27.27 0.0042
2018-11-13 2018-09-30 13F RETROPHIN COM 761299106 8,033 8,033 231 0.0046
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.